Teva Secures Global Rights to Polpharma Biologics’ Ocrelizumab Biosimilar, Expanding Multiple Sclerosis Portfolio
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Polpharma Biologics announced a global licensing agreement granting...
Teva Pharmaceutical
NeuroGen Pharma Secures NMPA Approval for Ajovy (Fremanezumab) in China, Launching First Quarterly CGRP Migraine Prevention Therapy
NeuroGen Pharma announced it has received marketing approval from China’s National Medical Products Administration (NMPA)...
Teva Launches Ahzantive Biosimilar to Bayer’s Eylea Across Europe – Expanding Access to Retinal Disease Treatments
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced the commercial launch of Ahzantive, its biosimilar version...
Teva to Acquire Emalex Biosciences for $700M, Adding Registration-Ready Tourette Syndrome Drug Ecopipam
Teva Pharmaceuticals Industries Ltd. (NYSE: TEVA) and Emalex Biosciences announced a definitive acquisition agreement under...
NeuroGen Pharma Secures Exclusive China Rights to Teva’s Ajovy – World’s First Dual-Indication CGRP Antagonist for Migraine Prevention
NeuroGen Pharma announced a strategic licensing agreement with Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), securing...
CTTQ and Teva Partner on Treanda Commercialization to Expand Bendamustine Access in China’s NHL Market
Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Ltd. (HKG:...
Fosun Pharma Secures NMPA Clearance for Two Novel Therapeutics: PD-1/IL-2 Fusion FXB0871 and Recombinant Hyaluronidase HLXTE-HAase02
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196, HKG: 2196) announced it has received clearance...
Fosun Pharma Secures NMPA Approval for Phase I Trial of ATTENUKINE™ Therapy FXB0871 in Solid Tumors
Fosun Pharma (SHA: 600196, HKG: 2196) has announced NMPA approval to initiate a Phase I...
Teva Secures FDA Approval for Prolia Biosimilar Ponlimsi, Advances Xolair Copycat Through Regulatory Channels
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) has announced FDA marketing approval for Ponlimsi, its biosimilar...
Teva Secures $400M Blackstone Funding for Duvakitug – TL1A Antibody Advances in IBD Phase III
Teva Pharmaceuticals (NYSE: TEVA) and Blackstone Life Sciences (BXLS) announced a $400 million strategic funding agreement over...
Fosun Pharma Collaborates with Teva on Development of TEV-56278 in China and Southeast Asia
China’s Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) and Israel-based Teva Pharmaceutical...
Teva Announces 8% Workforce Reduction to Achieve $700 Million Cost-Saving Goal
Israel-based Teva Pharmaceutical Industries Ltd (NYSE: TEVA) has disclosed plans to reduce its workforce by...
Sanofi and Teva’s Duvakitug Hits Key Milestones in UC and CD Study at ECCO Congress
Sanofi (EPA: SAN, NASDAQ: SNY) and Teva Pharmaceutical Industries Ltd (NYSE: TEVA) presented Phase IIb...
Samsung Bioepis and Teva Partner on Biosimilar EPYLLI for US Market
South Korea’s Samsung Bioepis and Israel-based Teva Pharmaceutical (NYSE: TEVA) have entered into a license,...
Teva Pharmaceutical to Divest Holdings in Teva Takeda Pharma to JKI
Israel-based Teva Pharmaceutical Industries Ltd (NYSE: TEVA) has announced its intention to sell all holdings...
Teva Pharmaceutical Expands Partnerships in China’s One Health Sector with New Agreements
Israel based Teva Pharmaceutical Industries Ltd (NYSE: TEVA) has announced new partnerships with Chinese firms...
Teva Pharmaceutical Reports Positive Phase III Results for TEV-‘749 in Schizophrenia Trial
Israel-based Teva Pharmaceutical Industries Ltd (NYSE: TEVA) has released new positive data on social functioning...
Teva’s Ajovy Achieves Positive Results in Phase III Migraine Prevention Trial in China
Teva Pharmaceutical Industries Ltd (NYSE: TEVA), headquartered in Israel, has announced positive results from a...
Alvotech Scores FDA Nod for Interchangeable High-Concentration Biosimilar to Humira
The US Food and Drug Administration (FDA) has granted approval to Iceland-based Alvotech’s (NASDAQ: ALVO)...
Jiangsu Nhwa Secures Exclusive Rights to Teva’s Austedo in China with $30 Million Deal
Jiangsu Nhwa Pharmaceutical Co., Ltd. (SHE: 002262), based in China, has entered into a cooperation...